bamlanivimab (Q100391783)

experimental antibody treatment for COVID-19

LY3819253
LY-CoV555

Language	Label	Description	Also known as
English	bamlanivimab	experimental antibody treatment for COVID-19	LY3819253 LY-CoV555

Statements

0 references

0 references

0 references

legal status (medicine)

boxed warning

1 reference

reference URL

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

title

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

developer

AbCellera

0 references

described by source

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

0 references

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

0 references

Identifiers

CAS Registry Number

2423943-37-5

0 references

PubChem Substance ID (SID)

434321760

0 references

434370493

0 references

World Health Organisation international non-proprietary name numeric ID

11876

0 references

Guide to Pharmacology Ligand ID

0 references

0 references

0 references

0 references

MedlinePlus drug identifier

a620062

0 references

Google Knowledge Graph ID

/g/11mvmfhsw_

0 references

WikiProjectMed ID

Bamlanivimab

0 references

bamlanivimab (Q100391783)

Statements

Identifiers

Sitelinks

Wikipedia(11 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

bamlanivimab (Q100391783)

Statements

Identifiers

Sitelinks

Wikipedia(11 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search